Gradoni Luigi, Gramiccia Marina, Scalone Aldo
Laboratorio di Parassitologia, Istituto Superiore di Sanità, Rome, Italy.
Emerg Infect Dis. 2003 Dec;9(12):1617-20. doi: 10.3201/eid0912.030178.
First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%. The countrywide change in therapy is a response to both disease reemergence and increasing antimonial failure.
在意大利，对573名免疫功能正常的内脏利什曼病患者进行了一线药物治疗记录。在过去12年中，锑剂治疗的比例从100%降至2.8%，而两性霉素B治疗的比例从0%升至97.2%。全国范围内治疗方法的改变是对疾病再次出现和锑剂治疗失败增加的一种应对措施。
